Magenta Therapeutics is a clinical-stage biotechnology company developing medicines to bring the curative power of stem cell transplant to more patients with blood cancers, genetic diseases and autoimmune diseases. Magenta is combining leadership in stem cell biology and biotherapeutics development with clinical and regulatory expertise, a unique business model and broad networks in the stem cell transplant community to revolutionize immune reset for more patients.Magenta is based in Cambridge, Mass. For more information, please visit www.magentatx.com.Follow Magenta on Twitter: @magentatx.

OrbiMed

Janus Henderson Investors

Deep Track Capital

Great Point Partners

TCG Crossover

EcoR1 Capital

The Watermill Group

Access Industries

Be The Match BioTherapies

Casdin Capital

Magenta Therapeutics

Gamida Cell Ltd is a clinical-stage biotechnology company focused on developing cell therapies for the treatment of cancer and rare genetic diseases.

Gamida Cell Ltd

Bluebird Bio Inc is a biotechnology company that develops gene therapies for severe genetic diseases and cancer.

Bluebird Bio Inc

Novartis AG is a multinational pharmaceutical company engaged in the research, development, manufacturing, and marketing of a range of healthcare products.

Novartis AG

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company focused on advancing next-generation antibody complement therapeutics.

Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops medicines to bring the curative power of stem cell transplants to patients with blood cancers, genetic diseases, and autoimmune diseases. It develops MGTA-117, an anti-CD117 antibody that targets hematopoietic stem cells (HSCs) and genetically mutated stem cells that cause acute myeloid leukemia and myelodysplastic syndromes, which is under Phase I/II clinical trial; CD45-antibody drug conjugate that targets HSCs and immune cells, which is in investigational new drug application enabling studies for potential use as a single-agent in autoimmune diseases and hematology-oncology transplants; and MGTA-145 that is in Phase II clinical trial for use in autologous and allogeneic transplants. The company also has a cell therapy program, E478, which is a small molecule aryl hydrocarbon receptor antagonist for stem cell-based gene therapy and genome editing. Magenta Therapeutics, Inc. has a research and clinical collaboration agreement with AVROBIO, Inc. for the treatment of lysosomal storage disorders; and Beam Therapeutics, Inc. to evaluate the potential utility of MGTA-117 for conditioning of patients with sickle cell disease and beta-thalassemia. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. Magenta Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Magenta Therapeutics, Inc.

industry_trends_dossier

news_impact_assignment_basic

key_people

company_dossier

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

network

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

events

strategic_challenges

network_mapping

industry_trends

transactions_dossier

strategic_challenges_dossier

financial_statements

network_onboarding

company_summary

signals

regulatory_analysis

industry_analysis

swot_dossier

competition_analysis

financial_legal_advisories

merger_acquisitions

swot_analysis

financial_analysis

news_advanced

purchaser_profile

news_impact_assignment_advanced

news_processing_advanced

peers

news_basic

valuation

customer_profile

industry trends dossier	dataroom
company dossier	dataroom
network	dataroom
network mapping	dataroom
transactions dossier	dataroom
network onboarding	dataroom
news impact assignment basic	general	Mar 4, 2024 11:55 PM	841ddb77
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Mar 4, 2024 11:55 PM	26137d9f
company summary	general
signals	general
news advanced	general
news impact assignment advanced	general
news processing advanced	general
peers	general
news basic	general	Mar 4, 2024 11:55 PM	06ee5dc3
events	markdown
bundesanzeiger	filings
financial statements	filings
regulatory analysis	company_analysis
industry analysis	company_analysis
competition analysis	company_analysis
financial legal advisories	company_analysis
merger acquisitions	company_analysis
swot analysis	company_analysis
financial analysis	company_analysis
purchaser profile	merger_acquisitions
customer profile	customers

COM:MAGENTATX

Dianthus Therapeutics, Inc.

Last Close

0.76

11/09 20:00

Market Cap

42.44M

Beta: -

Volume Today

375.91K

Avg: -